Due to the ongoing shortage of BCG, gemcitabine has been increasingly used for first-line NMIBC therapy. N-803’s ability to activate natural killer and CD8+ T cells, thus the innate immune system, to ...

Mycobacterial cell wall–DNA complex (MCC) is an effective treatment modality for bladder cancer, and has a favorable safety profile when compared with intravesical therapy using live bacillus ...

First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

J&J is developing a second Taris-derived candidate called TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), and has predicted that peak sales of the two ...

Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

If approved, TAR-200 will be the first intravesical drug-releasing system in the given indication. The FDA will review this submission under its Real-Time Oncology Review (“RTOR”) program.

Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment ...

Berlin, Germany, February 13, 2025 – Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the ...